FDA Approves Expanded Indication for Merck ’s Keytruda (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
KENILWORTH, N.J.--(BUSINESS WIRE) October 15, 2020 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Canada Health | Drugs & Pharmacology | Food and Drug Administration (FDA) | Lymphoma | Merck | USA Health